Fruquintinib

CAS : 1194506-26-7

Ref. 3D-FF137674

Informations sur le produit

• Nom: Fruquintinib
• Marque: Biosynth
• Description: Fruquintinib is an investigational drug that targets the cell signaling pathways involved in the progression of metastatic colorectal cancer and leukemia. It has been shown to inhibit the body's production of malonic acid, which is a precursor in the synthesis of collagen. Fruquintinib also inhibits choroidal neovascularization, a condition that can lead to blindness. The drug has been evaluated as a treatment option for renal cell cancer and malignant melanoma, with promising results. Fruquintinib binds to proteins in the blood and reaches its highest concentrations in plasma after one hour. The drug does not bind well to proteins in the gastrointestinal tract, which means that it is only minimally absorbed from this site of administration. Fruquintinib is metabolized extensively by cytochrome P450 enzymes and glucuronidases (UGTs) into metabolites that are excreted via urine and bile.

Propriétés chimiques

• Masse moléculaire: 393.39 g/mol
• Formule: C₂₁H₁₉N₃O₅
• Degré de pureté: Min. 95%